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Introduction
Myocardial infarction with non-obstructive coronary 
arteries (MINOCA) is a common and clinically im-
portant medical problem in the era of widespread 
use of coronary angiography. In the majority of 
studies on MINOCA, the analyzed populations of 
patients are dominated by females with an average 
age of 50–60 years. Compared to acute coronary 
syndrome (ACS) with obstructive coronary artery 
Abstract
Myocardial infarction with non-obstructive coronary arteries (MINOCA) as a relatively new disease entity distin-
guished from the group of acute coronary syndromes (ACS) is not a rare clinical problem and it requires in-depth 
diagnostics. MINOCA accounts for 5–10% of all ACS cases. MINOCA is most common between the ages of 50–60 
and predominates in females. Coronary microvascular dysfunction and coronary vasospasm are  among the potential 
mechanisms. The latest guidelines for the treatment of ACS in patients presenting without persistent ST-segment 
elevation emphasize the importance of searching for the causes of angina in patients with insignificant lesions in 
the coronary arteries by extending invasive diagnostics (e.g., acetylcholine provocation test) and using noninvasive 
diagnostics (e.g., CMR or SPECT). In the context of MINOCA, among the typical risk factors for coronary artery 
disease, arterial hypertension (HTN) seems to be the most important by inducing coronary microcirculation remod-
eling (mostly hypertrophy) and hence the narrowing of the lumen. Studies comparing patients with MINOCA and 
obstructive coronary artery disease (MI-CAD) in the context of risk factors, in particular HTN, were analyzed. In 
five out of nine analyzed studies, HTN occurred significantly more often in patients with MINOCA compared to 
patients with MI-CAD. The current pharmacotherapy recommendations focus on slowing the progression of coro-
nary microvascular dysfunction (CMD), i.e., adequate treatment of risk factors and comorbidities, such as HTN. 
Therefore, it seems reasonable to conduct studies directly analyzing the relationship between HTN and MINOCA 
in order to improve diagnostics and establish appropriate pharmacotherapy that will improve prognosis.
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disease (CAD), patients are less burdened with tradi-
tional risk factors such as diabetes, dyslipidemia, and 
smoking [1]. It is estimated that MINOCA accounts 
for 5–10% of all ACS cases [2]. MINOCA is more 
common as non-ST-elevation myocardial infarction 
(NSTEMI) than ST-elevation myocardial infarction 
(STEMI). At the same time, in-hospital mortality is 
lower compared to patients with obstructive coro-
nary artery disease (MI-CAD) [3].
The pathomechanism of MINOCA is not fully 
understood, and the underlying cause of the dis-
ease appears to be multifactorial. One of the poten-
tially important risk factors is arterial hypertension 
(HTN). In this review, we aimed to summarize the 
impact of HTN on MINOCA pathomechanisms as 
well as outcomes.
Etiopathogenesis
The pathogenesis of MINOCA appears to be varied. 
Eccentric plaques with positive remodeling can be 
prone to significant instability. Plaque disruption 
is followed by local thrombosis and then fibrino-
lysis, which may result in distal embolization. An 
angiographic image may suggest plaque rupture, but 
a final diagnosis can be made using higher-resolu-
tion optical coherence tomography (OCT) or, to 
a lesser extent, intravascular ultrasound (IVUS) [4]. 
Hereditary (e.g., factor V Leiden, von Willebrand 
factor) and acquired (thrombotic thrombocytopenia 
purple TTP, the autoimmune disorder antiphospho-
lipid syndrome, heparin-induced thrombocytopenia 
HIT) states may also predispose to coronary throm-
bosis or embolism. The small size myocardial infarc-
tion is best visualized in cardiac magnetic resonance 
(CMR).
Spontaneous dissection of the coronary artery 
(SCAD) is a rare mechanism of MINOCA but is not 
rarely observed as a cause of ACS in women under 50 
years of age. SCAD causes a significant obstruction 
of flow in most cases, but occasionally the vessels 
may appear normal due to the gradual narrowing of 
the distal artery lumen, indicating a possible cause of 
MINOCA [5].
The main pathophysiological mechanisms re-
sponsible for microvascular angina symptoms are 
coronary microvascular dysfunction (CMD) and 
vasospastic angina (VSA). They are considered pri-
marily responsible for ischemia with non-obstructive 
coronary arteries (INOCA) [6] and may manifest as 
MINOCA.
In the case of CMD, there is a remodeling of 
small arteries and arterioles. Hyperplasia and hy-
pertrophy change the smooth muscle system caus-
ing narrowing of the vessel lumen, which results in 
the reduction of the coronary reserve with clinically 
manifested angina [7]. Also, microcirculatory spasm 
might be responsible for CMD. It has been suggested 
that changes in microcirculation may precede those 
manifested in large vessels [8]. Arterial hypertension 
(HTN) is a crucial risk factor inducing the above-
mentioned pathological processes [9].
Coronary vasospasm (CVsp) is a broad subject 
involving structural CAD but may also coexist with 
CMD. Gender is a potent modifier of CVsp as the 
cause of INOCA is more common in men than in 
women [10]. Interestingly, it has also been noted that 
HTN is paradoxically negatively related to CVsp. 
This finding suggests that the pathogenesis of CVsp 
is distinct from that of coronary atherosclerosis [11].
Spontaneous CVsp is rare during routine coro-
nary angiography. And provocation tests are usually 
performed in tertiary centers, mainly with the use of 
intracoronary acetylcholine or ergonovine (intrave-
nous administration is also possible but not recom-
mended due to the high risk of death). Acetylcho-
line is injected intracoronary in gradually increasing 
doses. Graphs made on an ongoing basis show the 
extent of the contraction and its nature (diffuse or 
focal). Lumen reductions of 90% comparing to the 
reference after administration of nitroglycerin are 
interpreted as positive. The detailed diagnostic cri-
teria were prepared by COVADIS (Coronary Va-
somotor Disorders International) [12]. The joined 
use of adenosine and acetylcholine is used to assess 
endothelial independent and dependent dysfunc-
tion to differentiate between CMD and CVsp. After 
intracoronary administration of adenosine, the ar-
tery relaxes to its maximum. Coronary flow reserve 
(CFR) ≤ 2.0 in response to adenosine can diagnose 
endothelial-independent and endothelial-dependent 
CMD. Another invasive indicator is the index of 
microvascular resistance (IMR), which uses the phe-
nomenon of thermodilution with the help of a wire 
with a pressure and temperature sensor. Values ≥ 25 
U in the absence of epicardial stenosis indicate a dis-
turbance in blood flow through the microcirculation 
vessels [13]. Importantly, this parameter is indepen-
dent of hemodynamics, preload, afterload, and heart 
rate [14].
It is worth adding that the performance of these 
tests (i.e., CFR, IMR, provocative test with acetyl-
choline) during one procedure does not significantly 
extend the duration of the procedure but provides 
a complete set of relevant data [15]. In addition, 
when performing provocation tests, the extension 
of imaging diagnostics through the use of IVUS or 
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OCT may, apart from the diagnosis of CVsp, visual-
ize thrombus, vulnerable plaque, or SCAD, which 
forces the implementation of appropriate therapeutic 
measures [4, 16].
The AChPOL register examined, among other 
things, the feasibility and safety of provocative test 
with acetylcholine (AChT). Of the group of qualified 
patients (n=211), 99 had revealed variant angina, 
and 72 patients had a coronary microvascular spasm. 
During the 5-year follow-up, the group of patients 
with MINOCA and confirmed microvascular con-
traction had more frequent recurrences of angina 
and required hospitalization more often compared 
to patients with negative AChT. The study confirmed 
the popularization of AChT, which will increase the 
detection of CVsp, especially in patients with MI-
NOCA, and thus improve their prognosis [17].
Gender is a strong modifier of CVsp as the cause 
of INOCA is more common in men than in women 
[10]. Interestingly, it has also been noted that HTN 
is paradoxically negatively related to CVsp. This find-
ing suggests that the pathogenesis of CVsp is distinct 
from that of coronary atherosclerosis [11].
MINOCA in light of the latest guidelines
A new subsection on MINOCA has been included 
in the latest ESC Guidelines for the management 
of acute coronary syndromes in patients present-
ing without persistent ST-segment elevation. Fun-
damental to the diagnosis of MINOCA is cardiac 
troponin > 99th percentile of the upper reference 
level, but such rise of troponin may also be related 
to non-ischemic mechanisms. Based on the defini-
tion of ESC Fourth Universal Definition of Myo-
cardial Infarction, myocarditis, cardiomyopathy, and 
Takotsubo syndrome do not meet the criteria for the 
diagnosis of MINOCA [18]. Local wall contractility 
abnormalities may indicate an epicardial MINOCA 
cause or other specific causes that require further 
diagnosis. The essential tool in the differential diag-
nosis is CMR, which makes it possible to identify 
the cause in as many as 87% of MINOCA patients. 
Late enhancement after gadolinium administration 
in the sub-endocardium suggests an ischemic cause, 
while the sub-epicardial localization may indicate 
cardiomyopathies or myocarditis [16]. 
In July 2020, the position of the expert group 
of the European Association of Percutaneous Car-
diovascular Interventions (EAPCI) on INOCA was 
published. The document emphasizes that angina 
is the most common CAD symptom. The lack of 
confirmation in routine diagnostics should lead cli-
nicians to differentiate INOCA end-types before 
non-cardiac causes of chest discomfort.
In the search for the cause of impaired myocardial 
perfusion and ischemia, noninvasive tests, such as 
transthoracic Doppler echocardiography (TTDE), 
positron emission tomography (PET), single pho-
ton emission computed tomography (SPECT), or 
the CMR, as mentioned above, may be helpful. If 
INOCA is suspected during invasive diagnostics, 
additional diagnostic procedures (for example, pres-
sure and flow measurements and pharmacological 
coronary reactivity testing) should be implemented 
to distinguish the mechanism of CMD from va-
sospastic angina or non-cardiac pain. Moreover, it 
is recommended to perform fractional flow reserve 
(FFR) in patients with borderline stenosis in whom 
angioplasty is considered to be a procedure with 
a high benefit rate for the patient [6].
Correlation between hypertension and 
coronary artery disease
From 1990 to 2019, the number of adults worldwide 
suffering from hypertension increased from 2.18 bil-
lion to 4.06 billion, and the number of deaths from 
hypertension increased from 6.79 million to 10.8 
million [19]. Arterial hypertension is associated with 
an ongoing age-related risk of death from ischemic 
heart disease [20]. The correlation between HTN 
and MINOCA as a relatively new disease entity is 
important in establishing the most optimal phar-
macotherapy for the patient, reducing angina symp-
toms, and improving prognosis.
The frequently coexisting MINOCA risk factors 
such as aging, diabetes, and dyslipidemia lead to 
increased arterial stiffness and increased pulse pres-
sure. HTN affects the remodeling of small arteries, 
causing their hypertrophy, narrowing the lumen, and 
reducing blood vessels’ density. This contributes to 
CMD [9]. The effect of lowering blood pressure on 
improving CMD was studied by Mizuno et al. in 
2012. Patients with similar CFR results were en-
rolled in the study and reassessed after a 12-month 
treatment period with antihypertensive drugs. The 
analysis showed that lowering blood pressure is an 
independent determinant of improvement in CFR. 
It is noteworthy that excessive reduction of diastolic 
blood pressure weakened this effect [21].
In the aforementioned AChPOL Registry, a group 
of 45 patients with MINOCA was identified (in-
cluding 19 in the variant angina group, 23 in the 
microvascular spasm group, and three in the nega-
tive AChT group). Compared to patients without 
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a history of MINOCA, HTN was significantly more 
common in the MINOCA group (82.2% vs. 57.2%, 
p = 0.02). The study (as very promising) is definitely 
worth doing on a more extensive research sample, 
which would lead to an increased ability to detect 
differences [17].
The literature search yielded nine recent studies 
(including one meta-analysis covering 27 large clini-
cal trials/registries) attempting to characterize MIN-
OCA in the context of the clinical profile, prognosis, 
and MACE rates. The results were compared with 
those of patients with MI-CAD. The general studies’ 
conclusions are common and indicate that the prog-
nosis of patients is worse than previously believed, 
mainly in the context of cardiovascular events. In 
addition, each study identified HTN as a risk factor. 
The incidence of HTN in the MINOCA group in 
the analyzed studies ranged from 41.1% to 73.7%. 
It is worth adding that in 5 out of 9 analyzed studies, 
HTN as a risk factor occurred more frequently in 
MINOCA than in MI-CAD. The results are sum-
marized in Table 1.
Worth mentioning is also the study by Carrick et 
al., in which the pathophysiology of damage to the 
coronary microcirculation in patients with STEMI 
due to HTN was analyzed. Invasive and noninvasive 
reperfusion injury tests, circulating markers of in-
flammation, serial imaging of infarct pathology, and 
remodeling were conducted. HTN was not associ-
ated with acute reperfusion injury, as shown by di-
rect angiographic measurements (TIMI frame count, 
TIMI blush grade). A potential explanation comes 
from taking antihypertensive therapies with vasopro-
tective effect angiotensin-converting enzyme inhibi-
tors (ACE-I). However, the study results provided 
evidence that patients with HTN (as an independent 
risk factor) and acute STEMI had a worse prognosis 
due to microvascular injury within the infarct zone. 
Clinically, this was manifested by more frequent hos-
pitalizations for heart failure [30].
Treatment
The management of INOCA can be broken down 
into the influence of risk factors and antianginal 
medication. In patients with MINOCA, as in most 
patients with CAD, it is important to modify risk 
factors related to lifestyle in order to improve its 
quality and prognosis. Behavioral interventions can 
be carried out by nutritionists (low-fat, low-calorie 
diets), psychologists (coping with stress, obesity), 
nurses, or doctors [6].
The next stage of treatment is pharmacotherapy. 
Of the main risk factors for CAD, i.e., HTN, dys-
lipidemia, smoking, and diabetes, the main goal of 
treatment is adequate blood pressure control. This 
is due to a reduction in CMD progression and a re-
duction in the occurrence of angina symptoms. It is 
not easy as the MINOCA group of patients is often 
heterogeneous and diverse. That group of patients 
experience angina symptoms at least as frequently as 
patients after MI-CAD, and as they are not by defi-
nition candidates for revascularization, appropriate 
pharmacotherapy is paramount [23].
According to the latest reports, the use of be-
ta-blockers is associated with a significantly lower 
risk of mortality and major cardiovascular events. In 
contrast, the use of aspirin has a potentially detri-
mental effect on prognosis. These data seem to be im-
portant because standard therapy in secondary pre-
vention in patients after ACS with non-obstructive 
CAD may be unfavorable or even harmful for some 
patients. This is another argument forcing large-scale 
research to be carried out in the future to precisely 
characterize this disease entity [36].
Table 1. Comparison of the prevalence of arterial hypertension in patients with MINOCA and MI-CAD in individual studies
Trial MINOCA MI-CAD p value
% %
Eggers et al. [22] 41.1 43.2 0.001
Bil et al. [13] 52 45 > 0.05
Grodzinsky et al.[23] 68.8 63.4 0.037
Jánosi et al. [24] 73.7 79.1 < 0.05
Abdu et al. [25] 52.3 62.4 0.029
Rakowski et al. [26] 56.4 64.3 < 0.0001
Lopez-Pais et al. [27] 61.5 62.1 > 0.05
Raparelli et al. [28] 32.9 36.9 > 0.05
Vranken et al. [29] 48.6 43.2 > 0.05
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In relation to the 2018 ESC/EHA guidelines for 
the treatment of HTN, the main medications in 
patients with symptomatic angina are beta-blockers, 
for example, nebivolol 2.5–10 mg daily dose (reduc-
tion of myocardial oxygen consumption, antioxi-
dant properties) and calcium channel blockers, for 
instance, amlodipine 10 mg daily (vascular smooth 
muscle relaxation, reduction in myocardial oxygen 
consumption) [31]. The study by Neglia et al. from 
2011 confirmed the important role of using ACE-I 
in therapy, i.e., improvement in hyperemic myocar-
dial blood flow in hypertensive microvascular angina 
patients [32].
According to the EAPCI expert consensus, the use 
of ACE-I/ARB improves CFR in CMD. It should 
be noted that these drugs are easily combined in 
a single formulation with both beta-blockers and 
calcium channel blockers. The dominant role in the 
treatment of microvascular angina caused by CMD 
is played by to be beta-blockers and calcium channel 
blockers (in the next stage - nicorandil, ranolazine, 
ivabradine, trimetazidine). In patients with CVsp 
(after acetylcholine testing), calcium antagonists 
(e.g. high-dose diltiazem) should be considered as 
first-line treatment. Short-acting nitrates may require 
frequent repeated doses. On the other hand, the 
use of short-acting nitrates is often poorly tolerated, 
and it is believed that may increase symptoms in 
patients with microvascular angina. In patients with 
non-obstructive CAD, statins may also be effective. 
Moreover, in patients with CVsp and reduced CFR 
they exhibit anti-inflammatory properties [6].
In the summary of pharmacotherapy, it is also 
worth mentioning the ongoing study MINO-
CA-BAT. The primary objective of the study is to 
determine whether beta-blockade compared with no 
beta blockade and ACE-I / ARB compared with no 
ACE-I / ARB have an influence on lowering the 
occurrence of composite endpoint (i.e. death, re-
hospitalization for AMI, ischemic stroke, and heart 
failure). Though it has been long known that patients 
with MINOCA are at greater risk of cardiovascular 
events, so far no benefits from the use of secondary 
prophylactic therapies have been evaluated in ran-
domized trials. The results of MINOCA-BAT study 
may have an impact on guidelines for management 
of MINOCA [33].
Conclusions
MINOCA is still a new and often underestimated 
issue in cardiology. More research is needed to clarify 
the disease’s pathophysiology, improve diagnostics, 
and determine the appropriate, effective, and ad-
equate pharmacotherapy. It seems justified to con-
duct studies directly analyzing the relationship be-
tween arterial hypertension and MINOCA as an 
important etiological factor influencing this disease’s 
pathomechanism.
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